DISCOVER
A word from the President
With the new 2.0 era in the policy of competitive clusters, 2009 was an important year in our development. First of all, on July 6th, the French State and regional authorities renewed their trust in Lyonbiopole by signing the Performance Contract, a document that presents the cluster’s strategy, its aims, its action plan and the budget allocated for implementing these over the next three years. As well, Lyonbiopole’s Infectious Diseases Center opened on April 1st, 2009 and is now at full capacity. It hosts six research teams. This platform, one of a kind in Europe, was designed to meet the needs expressed by clusters members, in particular hosting public/private research teams and providing specialized facilities that enable innovative collaborative R&D projects in the field of infectious diseases.
Since 2005, 69 collaborative R&D projects have been accredited by Lyonbiopole, accounting for an overall investment of around € 419 million, for which € 169 million in public funding has been obtained from the French State, OSEO, regional authorities and the European Union. These results are the fruit of collective efforts. I would like to thank our public funding providers for their support and their commitment, as well as all of the members of Lyonbiopole’s Board of Directors and Technical Group, our partners, our members and the management team that assists you throughout the year in the development of your upcoming projects and collaborative ventures.
In 2010, the main objectives will be to strengthen our efforts for regarding funding and growth support of our SMBs as well as the emergence of collaborative projects and the preparation of the 3rd phase in the cluster development which should reach the creation of a real campus focused on technological innovation.
Philippe Archinard
President of Lyonbiopôle
They speak about...
« As a result of history vaccine research and industry are strongly present in the Rhône-Alpes region. With nearly half of its employees based in the region, Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, produces more than 1.6 billion doses of vaccine every year, enabling over 500 million people around the world to be vaccinated against 20 diseases. »
Jacques Berger
Sanofi Pasteur - Former Deputy Managing Director